[1]原梦飞,王娅辉,刘玉宁,等.金蝉益肾通络方调节SIRT1/自噬通路对抗糖尿病肾病足细胞衰老机制研究[J].陕西中医,2025,46(8):1023-1029.[doi:DOI:10.3969/j.issn.1000-7369.2025.08.003]
　YUAN Mengfei,WANG Yahui,LIU Yuning,et al.The mechanism of Jinchan Yishen Tongluo formula regulating SIRT1/autophagy pathway against podocyte aging in diabetic nephropathy[J].,2025,46(8):1023-1029.[doi:DOI:10.3969/j.issn.1000-7369.2025.08.003]
点击复制

金蝉益肾通络方调节SIRT1/自噬通路对抗糖尿病肾病足细胞衰老机制研究

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年8期
页码:
1023-1029
栏目:
基础研究
出版日期:
2025-08-05

文章信息/Info

Title:
The mechanism of Jinchan Yishen Tongluo formula regulating SIRT1/autophagy pathway against podocyte aging in diabetic nephropathy
作者:
原梦飞1; 王娅辉2; 刘玉宁1; 刘伟敬1; 孙鲁英1; 2
（1.北京中医药大学东直门医院,北京 100700；2.北京中医药大学房山医院,北京 102401）
Author(s):
YUAN Mengfei1; WANG Yahui2; LIU Yuning1; LIU Weijing1; SUN Luying1; 2
（1.Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine,Beijing 100700，China；2.Fangshan Hospital Affiliated to Beijing University of Chinese Medicine,Beijing 102401，China）
关键词:
糖尿病肾病; 金蝉益肾通络方; 足细胞; 自噬; 衰老; 沉默调节蛋白1
Keywords:
Diabetic nephropathy; Jinchan Yishen Tongluo formula; Podocyte; Autophagy; Aging; SIRT1
分类号:
R 587.2
DOI:
DOI:10.3969/j.issn.1000-7369.2025.08.003
文献标志码:
A
摘要:
目的：通过构建小鼠足细胞损伤模型，探讨金蝉益肾通络方（JCYSTL）调控沉默调节蛋白1（SIRT1）/自噬通路对抗糖尿病肾病（DN）足细胞衰老作用机制。方法：培养小鼠足细胞MPC5，以30 mmol/L高糖+10 μmol/L H2O2刺激足细胞72 h以模拟糖尿病肾损伤模型，分为Control组、Model组、金蝉益肾通络方（JCYSTL）组、JCYSTL+EX527组、白藜芦醇（Res）组。Western blot法检测SIRT1、LC3-Ⅱ、p62、p53、p21、nephrin及podocin蛋白水平；免疫荧光法检测SIRT1、LC3-Ⅱ、p62、p53、p21蛋白表达情况；鬼笔环肽染色检测足细胞骨架情况。结果：Model组SIRT1表达较Control组明显下降（P<0.05），JCYSTL可以提高SIRT1水平（P<0.05）；检测自噬指标发现，Model组LC3-Ⅱ、p62 水平明显升高（均P<0.05），JCYSTL可显著降低LC3-Ⅱ和p62水平（均P<0.05），但在加入SIRT1抑制剂EX527后LC3-Ⅱ和p62水平升高（均P<0.05）。检测衰老指标发现，Model组p53、p21水平较Control组升高（均P<0.05），JCYSTL可以下调p53、p21水平（均P<0.05），但加入SIRT1抑制剂EX527后p53、p21水平升高（均P<0.05）。检测足细胞损伤指标发现，Model组nephrin、podocin蛋白水平明显降低（均P<0.05），JCYSTL可提高nephrin、podocin蛋白表达（均P<0.05），加入SIRT1抑制剂后nephrin、podocin蛋白水平下降（均P<0.05）；JCYSTL可以改善足细胞骨架蛋白损伤。结论：JCYSTL通过上调SIRT1进而疏通自噬通路，发挥对抗足细胞衰老、减轻足细胞损伤的作用。
Abstract:
Objective:To explore the mechanism of Jinchan Yishen Tongluo formula (JCYSTL) regulating SIRT1/autophagy pathway to prevent diabetic nephropathy (DN) podocyte aging by establishing a mouse podocyte injury model.Methods:Mouse podocytes MPC5 were cultured and stimulated with 30 mmol/L high glucose +10 μmol/L H2O2 for 72 hours to simulate diabetic kidney injury model.They were divided into control group,model group,Jinchan Yishen Tongluo recipe (JCYSTL) group,JCYSTL+EX527 group and resveratrol (Res) group.The protein levels of SIRT1,LC3-Ⅱ,p62,p53,p21,nephrin and podocin were detected by Western blot.The expression of SIRT1,LC3-Ⅱ,p62,p53 and p21 proteins was detected by immunofluorescence.Phalloidin staining was used to detect the cytoskeleton of foot.Results:The expression of SIRT1 in the model group was significantly lower than that in the control group （P<0.05）,and JCYSTL treatment could increase the level of SIRT1 （P<0.05）.Autophagy index detection found that,the levels of LC3-Ⅱ and p62 in model group increased significantly （all P<0.05）,while those in JCYSTL group decreased significantly （P<0.05）,but after adding SIRT1 inhibitor EX527,the levels of LC3-Ⅱ and p62 increased （all P<0.05）.The detection of aging indicators found that,the levels of p53 and p21 in the model group were higher than those in the control group （all P<0.05）,the levels of p53 and p21 in the JCYSTL group could be decreased （all P<0.05）,but they were increased after adding SIRT1 inhibitor EX527 （all P<0.05）.Detection of podocyte injury index found that,the levels of nephrin and podocin in model group were significantly decreased （all P<0.05）,while those in JCYSTL group were increased （all P<0.05）.After adding SIRT1 inhibitor,the levels of nephrin and podocin decreased （all P<0.05）.JCYSTL can improve the injury of cytoskeleton protein in foot cells.Conclusion:Jinchan Yishen Tongluo formula can prevent podocyte aging and reduce podocyte damage by up-regulating SIRT1 and then dredging autophagy pathway.

参考文献/References:

[1]SUN H,SAEEDI P,KARURANGA S,et al.IDF diabetes atlas:Global,regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J].Diabetes Res Clin Pract，2022，183:109119.
[2]ALICIC R Z,ROONEY M T,TUTTLE K R.Diabetic kidney disease:Challenges,progress,and possibilities[J].Clin J Am Soc Nephrol,2017,12(12):2032-2045.
[3]李雨婷,蔡旭东,林晓蒙,等.温阳活血法改善微循环治疗糖尿病肾病研究进展[J].陕西中医,2025,46(1):139-141，145.
[4]SCHIRR-BONNANS S,COSTA N,DERUMEAUX-BUREL H,et al.Cost of diabetic eye,renal and foot complications:A methodological review[J].Eur J Health Econ,2017,18(3):293-312.
[5]AHOLA A J,HARJUTSALO V,FORSBLOM C,et al.Depression is associated with progression of diabetic nephropathy in type 1 diabetes[J].Diabetes Care,2021,44(1):174-180.
[6]PATEL D M,BOSE M,COOPER M E.Glucose and blood pressure-dependent pathways-the progression of diabetic kidney disease[J].Int J Mol Sci,2020,23，21(6):2218.
[7]SELBY N M,TAAL M W.An updated overview of diabetic nephropathy:Diagnosis,prognosis,treatment goals and latest guidelines[J].Diabetes Obes Metab,2020,22（1）:3-15.
[8]李泽,单伟,姜东.Maresin1对糖尿病大鼠肾脏损伤的保护作用及机制研究[J].陕西医学杂志,2022,51(12):1467-1471.
[9]郑玉草,解锆杰,苑天彤.糖尿病肾病中医治疗进展[J].云南中医中药杂志,2025,46(2):86-90.
[10]仝小林,黄一珊.糖尿病肾脏疾病中医药防治研究现状及发展对策[J].北京中医药大学学报,2022,45(12):1189-1195.
[11]刘伟敬,梁碧婵,胡海滢,等.“益气养阴通络法”通过调控SIRT1延缓糖尿病肾病进展的研究[J].中国中西医结合肾病杂志,2013,14(3):198-202.
[12]ZHENG Q Y,ZHANG X,GUO J,et al.Jinchan Yishen Tongluo Formula ameliorate mitochondrial dysfunction and apoptosis in diabetic nephropathy through the HIF-1α-PINK1-Parkin pathway[J].J Ethnopharmacol,2024,328:117863.
[13]赵晓露,谢淑华,潘庆军,等.蝉花对糖尿病大鼠肾小球沉默信息调节因子1表达的影响[J].中华实用诊断与治疗杂志,2014,28(12):1168-1171.
[14]刘伟敬,唐阳敏,谢淑华,等.蝉花菌丝对糖尿病肾病大鼠的肾脏保护作用机制研究[J].中国中西医结合肾病杂志,2014,15(8):665-668.
[15]YI C,MA M,RAN L,et al.Function and molecular mechanism of acetylation in autophagy regulation[J].Science,2012,336(6080):474-477.
[16]CUI Z,ZHAO X,AMEVOR F K,et al.Therapeutic application of quercetin in aging-related diseases:SIRT1 as a potential mechanism[J].Front Immunol,2022,13:943321.
[17]TERVAERT T W,MOOYAART A L,AMANN K,et al.Pathologic classification of diabetic nephropathy[J].J Am Soc Nephrol,2010,21(4):556-563.
[18]KITTADA M,OGURA Y,MONNO I,et al.Regulating autophagy as a therapeutic target for diabetic nephropathy[J].Curr Diab Rep,2017,17(7):53.
[19]KAUFMANN A,BEIER V,FRANQUELIM H G,et al.Molecular mechanism of autophagic membrane-scaffold assembly and disassembly[J].Cell,2014,156(3):469-481.
[20]WATROBA M,DUDEK I,SKODA M,et al.Sirtuins,epigenetics and longevity[J].Ageing Res Rev,2017,40:11-19.
[21]CHEN C,ZHOU M,GE Y,et al.SIRT1 and aging related signaling pathways[J].Mech Ageing Dev,2020,187:111215.
[22]SACCONNAY L,CARRUPT P A,NURISSO A.Human sirtuins:Structures and flexibility[J].J Struct Biol,2016,196(3):534-542.
[23]ZHONG Y,LEE K,HE J C.SIRT1 is a potential drug target for treatment of diabetic kidney disease[J].Front Endocrinol (Lausanne),2018,9:624.
[24]HASEGAWA K,WAKINO S,SIMIC P,et al.Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes[J].Nat Med,2013,19(11):1496-1504.
[25]KITADA M,TAKEDA A,NAGAI T,et al.Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats:A model of type 2 diabetes[J].Exp Diabetes Res,2011,2011:908185.
[26]WANG L,XIE X,CHEN Q,et al.Puerarin reduces diabetic nephropathy-induced podocyte pyroptosis by modulating the SIRT1/NLRP3/caspase-1 pathway[J].Mol Cell Endocrinol,2025,595:112409.
[27]GOLIGORSKY M S.SIRTing out the link between autophagy and ageing[J].Nephrol Dial Transplant,2010,25(8):2434-2436.
[28]LEE I H,CAO L,MOSTOSLAVSKY R,et al.A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy[J].Proc Natl Acad Sci U S A,2008,105(9):3374-3379.
[29]MA L,FU R,DUAN Z,et al.Sirt1 is essential for resveratrol enhancement of hypoxia-induced autophagy in the type 2 diabetic nephropathy rat[J].Pathol Res Pract,2016,212(4):310-318.
[30]MOHANDES S,DOKE T,HU H,et al.Molecular pathways that drive diabetic kidney disease[J].J Clin Invest,2023,133(4):e165654.
[31]张炜捷,朱戎.基于足细胞上皮-间充质转化探讨中医药对慢性肾脏疾病作用机制及研究进展[J].陕西中医,2024,45(9):1294-1297.

相似文献/References:

[1]张华贞.复方黄芪汤加减联合骨化三醇治疗糖尿病肾病疗效及对患者血糖、肾功的影响*[J].陕西中医,2019,(6):767.
[2]程红卫,成晓萍.阎晓萍从脾论治糖尿病肾病经验总结*[J].陕西中医,2019,(6):790.
[3]黄聪丽,王治新△.益气滋肾活血通络方治疗早中期糖尿病肾病临床研究[J].陕西中医,2019,(10):1390.
　HUANG Congli,WANG Zhixin..Clinical efficacy analysis of Yiqi Zishen Huoxue Tongluo decoctionon early and medium stage of diabetic nephropathy[J].,2019,(8):1390.
[4]玉山江·艾克木,哈丽达·木沙△,地丽尼嘎尔.西红康联合还原型谷胱甘肽治疗2型糖尿病肾病Ⅲ期气阴两虚夹瘀证疗效及对患者微炎症状态、抗氧化的影响*[J].陕西中医,2020,(3):338.
　Yushanjiang·Aikemu,Halida·Musha,Dilinigaer..Efficacy of adjuvant therapy of Xihongkang on type 2 diabetic nephropathy Ⅲ phase with syndrome of Qiyin Liangxu Jiayu type and its effect on micro inflammation and antioxidant role[J].,2020,(8):338.
[5]马民凯,马红建,陈新苗.通络散结汤对3期糖尿病肾病患者GFR、UAER、β2-MG、Cys-C及微炎症状态的影响*[J].陕西中医,2020,(10):1432.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.025]
[6]田娟娟,陈 强,周欣欣,等.益气养阴活血法治疗糖尿病肾病理论探究*[J].陕西中医,2020,(12):1781.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.026]
[7]代广玉,修丽梅.糖尿病肾病中医辨证分型研究进展[J].陕西中医,2021,(1):131.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.036]
[8]赵 亚,张勉之,樊威伟,等.国医大师张大宁治疗糖尿病肾病用药经验[J].陕西中医,2021,(6):773.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.025]
[9]张 蕊,王子承,蒋荣莉,等.防己黄芪汤加味治疗糖尿病肾病疗效及对患者糖脂代谢、氧化应激的影响[J].陕西中医,2021,(8):1049.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.015]
　ZHANG Rui,WANG Zicheng,JIANG Rongli,et al.Effect of Fangji Huangqi decoction on diabetic nephropathy and its influence on glucose and lipid metabolism and oxidative stress[J].,2021,(8):1049.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.015]
[10]方锦颖,王一冲,神原优滋(日本),等.基于网络药理学和分子对接探究肾康注射液治疗糖尿病肾病作用机制[J].陕西中医,2021,(12):1798.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.039]

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82305206，8227141261）；国家重点研发计划项目（2018YFC1704304）
更新日期/Last Update: 2025-08-08